Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. reports developments in model-informed drug development, combining biosimulation software, technology and services for drug discovery, clinical development and regulatory science. Company news frequently centers on quarterly results, revenue mix between software and services, guidance updates and operating changes following the completed divestiture of its global medical writing and related regulatory services business.
Recurring updates also cover strategic partnerships with drug-development service providers and the use of Certara's Simcyp® Simulator for physiologically based pharmacokinetic modeling. These announcements describe biosimulation applications in clinical pharmacology, new drug applications and regulatory decision-making for biopharmaceutical, academic and agency clients.
Certara has priced its upsized initial public offering (IPO) of 29,055,000 shares of common stock at $23.00 per share, aiming to raise approximately $336.5 million before expenses. The offering, scheduled to close on December 15, 2020, involves 14,630,000 shares from Certara and 14,425,000 from selling stockholders. Shares will trade on Nasdaq under the ticker 'CERT' starting December 11, 2020. A 30-day option for underwriters to purchase an additional 4,358,250 shares is also part of the offering.
Certara, known for its biosimulation technology, has announced the launch of its initial public offering (IPO) of 24,390,000 shares of common stock, with prices expected between $19.00 and $22.00 per share. The offering comprises 14,630,000 shares from Certara and 9,760,000 shares from selling stockholders, who will also give underwriters a 30-day option for an additional 3,658,500 shares. Certara's shares will be listed on Nasdaq under the symbol "CERT." The company will not receive proceeds from shares sold by selling stockholders.